Navigation Links
CEL-SCI Corporation Announces 2008 Financial Results
Date:1/14/2009

harmaceuticals and Orient Europharma), joint ventures and/or financings to start the Phase III clinical trial with its cancer drug Multikine. In addition, in late December 2008 CEL-SCI put in place a $5 million equity line of credit. In the meantime, in light of the challenging capital markets, management has been very successful in reducing its monthly cash expenditures.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.

                                CEL-SCI CORPORATION
                        CONSOLIDATED STATEMENTS OF OPERATIONS
                       YEARS ENDED SEPTEMBER 30, 2008 and 2007

   
'/>"/>
SOURCE  CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 

Related biology technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
3. CEL-SCI Takes Delivery of New Manufacturing Facility
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
6. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
7. CEL-SCI to Present at the Noble Financial Conference
8. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
9. Mach One Corporation Enters Letter of Intent
10. Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
11. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
(Date:5/16/2013)... Kitware , a leading provider of scientific ... SBIR funding from the U.S. Department of Energy ... performance computing (HPC) simulation and computation framework. The ... only the toolkits and applications needed to perform ... , Manufacturers increasingly rely on simulation tools ...
(Date:5/16/2013)... On average, developing a new drug ... dollars. Despite this investment, less than 10% of drugs ... your clinical trial design optimally structured to balance time, ... Dr. Frederic Sax, Global Head of the Center for ... data, information and technology in upfront clinical trial planning ...
(Date:5/16/2013)... Dr. Stephen Y. Chou, Founder of Nanonex Corporation, will ... at IEEE Nano 2013 in Beijing, China, on August ... is becoming one of the most critical nanofabrication technologies ... resolution, large area, and low cost unmatchable by other ... in a broad range of industries, from ICs, nano/micro ...
Breaking Biology Technology:ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... Mass., May 14 Cynosure, Inc.,(Nasdaq: CYNO ... broad array of,light-based aesthetic treatment systems, today announced ... of global marketing. Lee will develop and,implement worldwide ... including the Smartlipo MPX, the company,s newest system,for ...
... MONTVALE, N.J., May 14 Memory Pharmaceuticals,Corp. (Nasdaq: ... for the first,quarter ended March 31, 2008., ... significant progress with,our collaborations and refocusing our operations ... President and Chief Executive Officer.,"Roche,s recent decision to ...
... StemCor Systems, Inc., a,medical device company developing ... it has been awarded a,National Institutes of Health ... "Adult Stem Cell Minimally Invasive Bone Marrow,Harvester." The ... received 510(k) clearance from the U.S. Food and ...
Cached Biology Technology:Cynosure Appoints H. Travis Lee as Vice President of Global Marketing 2Cynosure Appoints H. Travis Lee as Vice President of Global Marketing 3Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 7StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 2StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 3
(Date:5/17/2013)... An international team of scientists using a new X-ray ... a living frog embryo in greater detail than ever ... biological research and the search for new treatments for ... Institut fr Technologie in Germany, in collaboration with the ... Argonne National Laboratory, released the most precise depiction ever ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Endocrine Society (ENDO) 95th Annual Meeting in ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the ENDO 2013 Annual Meeting. , Awards are ...
(Date:5/16/2013)... African-American adults living closer to a fast food restaurant ... who lived further away from fast food, according to ... Center, and this association was particularly strong among those ... published online in the American Journal of Public ... to a fast food restaurant, and among lower-income African-Americans, ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... NEW YORK (FEBRUARY 13, 2008) The Wildlife Conservation ... a 5,000 mile-long genetic corridor from Bhutan to Burma ... landscapes. The corridor, first announced at the United Nations ... the largest block of tiger habitat left on earth. ...
... In an innovative program to help junior researchers, particularly ... American Society for Cell Biology (ASCB) today announced that ... for child care during the Societys 2008 Annual Meeting, ... Goldberg said that the $16,000 New Scholars grant from ...
... Washington Laws protecting the critically endangered Sumatran Tiger ... sold in Indonesia, according to a TRAFFIC report launched ... skin pieces, whiskers and bones, were on sale in ... 2006 in 28 cities and towns across Sumatra. Outlets ...
Cached Biology News:'Genetic corridors' are next step to saving tigers 2'Genetic corridors' are next step to saving tigers 3Cell biologists announce child-care grants for scientist-parents at annual meeting 2Body part by body part, Sumatran tigers are being sold into extinction 2
Amyloid stain....
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Adhesion Molecule Antibodies...
Biology Products: